中国宝安去年盈利1.73亿元，核心企业及业务竞争优势增强

Core Insights - China Baoan reported a significant decline in both revenue and net profit for the year 2024, with total revenue of 20.23 billion yuan, down 34.10% year-on-year, and net profit attributable to shareholders of 172.63 million yuan, down 77.18% year-on-year [1][2][3] Financial Performance - Total assets increased by 7.33% year-on-year, reaching approximately 53.77 billion yuan at the end of 2024 [2] - Net assets attributable to shareholders slightly decreased by 0.18% year-on-year, totaling approximately 9.91 billion yuan [2] - The company’s basic earnings per share dropped by 77.19% to 0.0669 yuan [2] - The weighted average return on equity fell to 1.73%, down 6.18% from the previous year [2] Business Segments - The company is transitioning to an investment group focused on new materials, with its subsidiary, BetterRay, being a key player in the production of anode materials [2][3] - BetterRay achieved a sales volume of over 430,000 tons of anode materials, with a year-on-year increase in overall gross margin [2][3] - The biopharmaceutical segment, represented by Mayinglong, reported a total revenue of 3.73 billion yuan, an increase of 18.85% year-on-year, and a net profit of 528 million yuan, up 19.14% year-on-year [3] Strategic Developments - BetterRay is enhancing its global supply chain resilience through projects in Indonesia and Morocco, including an integrated project in Indonesia with an annual capacity of 80,000 tons of lithium battery anode materials [3] - The company is also investing in new technology directions such as fast-charging anode materials, hydrogen energy, sodium-ion battery materials, solid-state battery materials, and silicon-based anode materials [3]